



**Alliance for Clinical Trials in Oncology 2014 Fall Group Meeting  
Clinical Research Professionals Education Meeting Agenda  
Saturday, November 8, 2014  
8 am – 12 pm**

<b>8 am</b>	<b>Opening and Welcome</b>	<i>Jennifer Dill, CCRP, CRP Committee Chair</i>
<b>8:05 am</b>	<b>S1400 Master Lung Protocol, “Phase II/III Biomarker-Driven Master Protocol for Second Line Therapy of Squamous Cell Lung Cancer</b>	<i>Vassiliki A. Papadimitrakopoulou, MD Professor of Medicine Department of Thoracic/HN Medical Oncology Jay and Lori Eisenberg Endowed Professor MD Anderson Cancer Center, Houston, TX</i>
<b>9:05 am</b>	<b>(ALCHEMIST) -Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials A151216–Screening Component A081105-EGFR Treatment Component E4512-ALK Treatment Component</b>	<i>Olwen Hahn, MD Assistant Professor Section of Hematology-Oncology University of Chicago Executive Officer, Alliance for Clinical Trials in Oncology</i>
<b>10:05 am</b>	<b><i>BREAK</i></b>	
<b>10:20 am</b>	<b>A071101 A Phase II Randomized Trial Comparing the Efficacy of Heat Shock Protein-Peptide Complex-96 (HSPPC-96)(NSC #725085, Alliance IND#15380) Vaccine Given with Bevacizumab Versus Bevacizumab Alone in the Treatment of Surgically Resectable Recurrent Glioblastoma Multiforme (GBM)</b>	<i>Andrew Parsa, MD UCSF Mt Zion  Parisa Mirzadehgan, MPH, CCRP Cedars-Sinai Medical Center</i>
<b>11:20 am</b>	<b>The Clinical Trial Assessment of Infrastructure Matrix Tool (CT AIM) to Improve the Quality of Research Conduct in the Community</b>	<i>Kandie Dempsey, MS, RN, OCN Delaware/Christiana Care NCI Community Oncology Research Program (NCORP)</i>
<b>12 pm</b>	<b>Evaluations/Closure</b>	

**\*\*\*CE CREDIT SESSIONS MARKED IN BLUE**